COSA 2021: Pertuzumab + Standard Treatment of HER2-Positive Breast Cancer Improves pCR
Real world subjects were treated neoadjuvantly for early disease.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Real world subjects were treated neoadjuvantly for early disease.
Only registered members have full access to PracticeUpdate content.